Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12248)	11/17/1999 1:09:00 AM
From: LarryS	Read Replies (1) \| Respond to of 17367

Good find George...can't wait until the science guys get on here with their input. Even a layman could understand from the statements that BPI sure seems like a winner...and not just as a one shot application but for several new uses over the next several years. I just wish it would get approved....and soon. The patent is owned by the US govt...is that going to effect Xoma?

To: aknahow who wrote (12248)	11/17/1999 7:27:00 AM
From: Robert K.	Respond to of 17367

clues to changes> rBPI-21 IV formulation (NEUPREX©) meningococcemia Phase III 393 patients, enrollment complete hemorrhage due to trauma Phase III 1650 patients severe intra-abdominal infections Phase I/II dose-related benefits in 21 patients partial hepatectomy Phase II 35 patient study, article submitted pulmonary exacerbations in cystic fibrosis patients Phase I 15-patient PK/safety study complete rBPI-21 combination topical anti-infectives ophthalmic infections, corneal ulcers Preclinical licensed to Allergan rBPI-21 topical formulation (I-PREX(tm)) ophthalmic infections prophylaxis Preclinical Strategic partner discussions BPI-Derived Peptides fungicidal compounds (Mycoprex(tm)) systemic fungal infections Preclinical Strategic partner discussions anti-angiogenic chronic infalmmatory diseases, metastatic tumors Preclinical Internal program All above from xoma site. Take it for what you will.